"Dan L Duncan Comprehensive Cancer Center at Baylor St. Luke's Medical Centeris dedicated to delivering high quality, compassionate care to Houston, TX and nearby communities. Visit us at7200 Cambridge Stor call 7137982262for more information. Our physicians are committed to building long-lasting relationships with their patients and families. Our board-certified physicians provide continuous patient-centered care, while using the latest technology for diagnosis and treatment."

During the past decade, Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center conducted 156 clinical trials. In the 10-year time frame, 156 clinical trials started and 95 clinical trials were completed, i.e. on average, 60.9% percent of trials that started reached the finish line to date. In the past 5 years, 63 clinical trials started and 67 clinical trials were completed. i.e. 106.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center" #1 sponsor was "National Cancer Institute (NCI)" with 113 trials, followed by "Children's Oncology Group" with 83 trials sponsored, "SWOG Cancer Research Network" with 21 trials sponsored, "Alliance for Clinical Trials in Oncology" with 12 trials sponsored and "Baylor College of Medicine" with 12 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 136 trials as a collaborator, "NRG Oncology" with 8 trials as a collaborator, "Canadian Cancer Trials Group" with 7 trials as a collaborator, "Children's Oncology Group" with 7 trials as a collaborator and "Cancer and Leukemia Group B" with 4 trials as a collaborator. Other collaborators include 42 different institutions and companies that were collaborators in the rest 39 trials.

According to Clinical.Site data, the most researched conditions in "Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center" are "Recurrent Malignant Solid Neoplasm" (31 trials), "Refractory Malignant Solid Neoplasm" (29 trials), "Recurrent Neuroblastoma" (26 trials), "Recurrent Osteosarcoma" (23 trials) and "Refractory Neuroblastoma" (20 trials). Many other conditions were trialed in "Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center" in a lesser frequency.

Most popular intervention types in "Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center" are "Drug" (189 trials), "Other" (173 trials), "Procedure" (89 trials), "Biological" (88 trials) and "Radiation" (54 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (110 trials), "Questionnaire Administration" (51 trials), "Quality-of-Life Assessment" (50 trials), "Cyclophosphamide" (44 trials) and "Pharmacological Study" (42 trials). Other intervention names were less common.

The vast majority of trials in "Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center" are 232 trials for "All" genders, 17 trials for "Female" genders and 10 trials for "Male" genders.

Currently, there are NaN active trials in "Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center". undefined are not yet recruiting, 70 are recruiting, 113 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 65 completed trials in Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, 5 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, 41 "Phase 1" clinical trials were conducted, 101 "Phase 2" clinical trials and 109 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 8 trials that are defined as “Not Applicable".